

## THE PRIMARY CARE COMPANION FOR CNS DISORDERS

## **Supplementary Material**

**Article Title:** Noninterventional, Naturalistic, Retrospective Study to Describe Prescription Patterns of Long-Acting Injectable Antipsychotics and the Impact of Introducing a New Atypical Antipsychotic in the Tarragona Catchment Area

**Author(s):** Ana M. Gaviria, PhD; José Franco, PhD; Guillem Rico, DI; Gerard Muntané, PhD; Cristina Sáez, MD; Vanessa Sánchez-Gistau, PhD; Joan de Pablo, PhD; and Elisabet Vilella, PhD

**DOI Number:** https://doi.org/10.4088/PCC.16m02044

## **List of Supplementary Material for the article**

- Table 1
- 2. Figure 1


## **Disclaimer**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Table 1. Demographic and clinical characteristics of patients with long (≥5 years) and short (<5 years) disease evolution

Variable	≥5 years	<5 years	Statistic p-value
N	1317	329	•
Gender			X <sup>2</sup> =9.25, p=0.00236
Male	884 (67.1%)	250 (76%)	·
Female	433 (32.9%)	79 (24%)	
Age (years, mean ± SD)	45.5±13.8	36.9±10.3	D=0.27, p<0.001
Marital status			X <sup>2</sup> =15.73, p=0.0034
Single	918 (69.7%)	215 (65.3%)	·
Married / Domestic Partner	175 (13.3%)	46 (14%)	
Separated / Divorced	75 (5.7%)	13 (4%)	
Widowed	20 (1.5%)	1 (0.3%)	
Unknown/Not reported	129 (9.8%)	54 (16.4%)	
Schizophrenia subtype	, ,	,	X <sup>2</sup> =26.48, p<0.001
Paranoid	941 (71.5%)	260 (79%)	• •
Hebephrenic	38 (2.9%)	3 (0.9%)	
Catatonic	2 (0.2%)	2 (0.6%)	
Undifferentiated	75 (5.7%)	17 (5.2%)	
Post-schizophrenic depression	-	1 (0.3%)	
Residual	155 (11.8%)	15 (4.6%)	
Simple	47 (3.6%) <sup>′</sup>	13 (4%)	
Other	10 (0.8%)	3 (0.9%)	
Unspecified	49 (3.7%)	15 (4.6%)	
Principal Antipsychotic	, ,	, ,	X <sup>2</sup> =9.802, p=0.0017
Typical	237 (18%)	35 (10.6%)	, р стост
Atypical	1080 (82%)	294 (89.4%)	
Antipsychotics Pattern	(0=70)		X <sup>2</sup> =9.30, p=1
Monotherapy	398 (30.2%)	99 (30.1%)	. О.ОО, р
Polypharmacy	919 (69.8%)	230 (69.9%)	
Neuropsychiatric co-medication	1080 (82%)	270 (82%)	X <sup>2</sup> =0, p=1
Anticonvulsants	419 (31.8%)	113 (34.3%)	·
Anticholinergics	428 (32.5%)	91 (27.7%) <sup>°</sup>	
Anxiolytics	664 (50.4%)	148 (45%)	
Hypnotics / sedatives	426 (32.3%)	110 (33.4%)	
Antidepressants	481 (36.5%)	138 (42%)	
Presence of psychiatric co-	501 (38%)	143 (43.5%)	$X^2=3.03$ , p=0.082
morbidity	00 (00()	44 (0.00()	
Affective disease	26 (2%)	11 (3.3%)	
Personality disease	29 (2.2%)	9 (2.7%)	
Intellectual disability	20 (1.5%)	9 (2.7%)	
Substance abuse consumption disease	387 (29.4%)	88 (26.7%)	
Presence of consumption of	414 (31.43%)	99 (30%)	X <sup>2</sup> =3.6, p=0.058
substances .	, ,	, ,	<i>'</i> !
Tobacco	343 (26%)	80 (24.3%)	
Alcohol	106 (8%)	16 (4.8%)	
Cannabis	70 (5.3%)	19 (5.8%)	
Cocaine	23 (1.7%)	8 (2.4%)	

 $Figure \ 1.$  Frequency of patients treated with LAI



It is illegal to post this copyrighted PDF on any website. ♦ © 2017 Copyright Physicians Postgraduate Press, Inc.